|
 |
|
|||||||
|
|||||||||
Diabetes 51:2612-2618, 2002
© 2002 by the American Diabetes Association, Inc.
Effects of Mesangium Glycation on Matrix Metalloproteinase Activities
Possible Role in Diabetic Nephropathy
From the Department of Endocrinology, Royal Prince Alfred Hospital, and Department of Medicine, University of Sydney, Sydney, NSW, Australia
High glucose concentrations can decrease degradation of mesangium by reducing the activities of matrix metalloproteinases (MMPs). The aim of this study was to investigate the effects of glycation of mesangium matrix on MMP-2, the principal MMP secreted by mesangial cells to degrade type IV collagen. Also examined were membrane type 1 MMP (MT1-MMP), tissue inhibitors of MMPs (TIMP)-1 and -2, and transforming growth factor-ß (TGF-ß), which together regulate MMP-2 activities in an interacting manner. Human fetal mesangial cells were grown on mesangium matrix glycated by incubation in 500 mmol/l ribose, with or without aminoguanidine. The activities and gene expression of the abovementioned enzymes/inhibitors were measured by degradation of radiolabeled mesangium matrix, RT-PCR, and zymography. Glycation of mesangium matrix resulted in a threefold increase in advance glycation end products and reduced by 45% the matrix-degrading activity of MMPs secreted by mesangial cells. Analogous to the direct effects of high glucose concentrations, glycation of matrix increased the gene expression of MMP-2 and TIMP-1 (control 100 ± 16.9 vs. glycated 197.3 ± 30.6% and control 100 ± 5.3 vs. glycated 152.1 ± 20.1%, respectively; P < 0.05) and decreased MT1-MMP (control 100 ± 1.17 vs. glycated 54.1 ± 15.2%; P < 0.05). However, unlike high glucose concentrations, glycation was not associated with decreased activation of MMP-2. Similarly, glycation but not high glucose increased expression of TIMP-2 (control 100 ± 5.9 vs. glycated 168.2 ± 31.4%; P < 0.05), and the effects of glycation on degradation can be abolished by anti-TIMP-2 antibody. Glycation of matrix decreased TGF-ß mRNA by 38.2% and total and active TGF-ß by 35.5 and 21.5%, respectively, opposite the effects of high glucose concentrations. Our results indicate that glycation of matrix affects the balance between MMP-2 and its activator and inhibitors, but this phenomenon is not due to TGF-ß. The process of glycation may impart to the mesangium matrix a memory effect that contributes to the long-term toxicity of hyperglycemia.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Hiden, E. Glitzner, M. Ivanisevic, J. Djelmis, C. Wadsack, U. Lang, and G. Desoye MT1-MMP Expression in First-Trimester Placental Tissue Is Upregulated in Type 1 Diabetes as a Result of Elevated Insulin and Tumor Necrosis Factor-{alpha} Levels Diabetes, January 1, 2008; 57(1): 150 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Han, Y. H. Jee, K. H. Han, Y. S. Kang, H. K. Kim, J. Y. Han, Y. S. Kim, and D. R. Cha An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2406 - 2416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Rodriguez, N. Tyagi, I. G. Joshua, J. C. Passmore, J. T. Fleming, J. C. Falcone, and S. C. Tyagi Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus Am J Physiol Renal Physiol, September 1, 2006; 291(3): F694 - F701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Wang, S. X. Zhang, R. Mott, R. R. Knapp, W. Cao, K. Lau, and J.-x. Ma Salutary Effect of Pigment Epithelium-Derived Factor in Diabetic Nephropathy: Evidence for Antifibrogenic Activities Diabetes, June 1, 2006; 55(6): 1678 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Portik-Dobos, A. K. Harris, W. Song, J. Hutchinson, M. H. Johnson, J. D. Imig, D. M. Pollock, and A. Ergul Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R435 - R441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Genuth, W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, W. Sivitz, V. M. Monnier, and for the DCCT Skin Collagen Ancillary Study Group Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes Diabetes, November 1, 2005; 54(11): 3103 - 3111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis Matrix Metalloproteinases and Diabetic Vascular Complications Angiology, March 1, 2005; 56(2): 173 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 S. V. McLennan, X. Y. Wang, V. Moreno, D. K. Yue, and S. M. Twigg Connective Tissue Growth Factor Mediates High Glucose Effects on Matrix Degradation through Tissue Inhibitor of Matrix Metalloproteinase Type 1: Implications for Diabetic Nephropathy Endocrinology, December 1, 2004; 145(12): 5646 - 5655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko Diabetic Somatic Neuropathies Diabetes Care, June 1, 2004; 27(6): 1458 - 1486. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Forbes, M. E. Cooper, M. D. Oldfield, and M. C. Thomas Role of Advanced Glycation End Products in Diabetic Nephropathy J. Am. Soc. Nephrol., August 1, 2003; 14(90003): S254 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mason and N. A. Wahab Extracellular Matrix Metabolism in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1358 - 1373. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |